Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

PharmacoEconomics

Showing results (21-30 of 3,928) with videos related to

Pageof 393
Sort By:
Pharmacoeconomics|January 8, 2016
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling StudyKathryn Coyle, Doug Coyle, Julie Blouin, et al.
Pharmacoeconomics|January 22, 2016
Biosimilars: How Can Payers Get Long-Term Savings?Jorge Mestre-Ferrandiz, Adrian Towse, Mikel Berdud
Pharmacoeconomics|December 31, 2015
Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life CareJoanna Coast, Elisabeth Huynh, Philip Kinghorn, et al.
Pharmacoeconomics|December 31, 2015
Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?Beth Woods, Rita Faria, Susan Griffin
Pharmacoeconomics|February 11, 2016
Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search RequirementSuzy Paisley
Pharmacoeconomics|May 27, 2016
Model Validation: Has it's Time Come?Jonathan Karnon
Pharmacoeconomics|June 3, 2016
Sustainable Financing of Innovative Therapies: A Review of ApproachesAidan Hollis
Pharmacoeconomics|February 26, 2016
Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and ChallengesSevan Dirmesropian, James G Wood, C Raina MacIntyre, et al.
Pharmacoeconomics|April 13, 2016
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with SchizophreniaKrithika Rajagopalan, David Trueman, Lydia Crowe, et al.
Pharmacoeconomics|February 20, 2016
Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group PerspectiveP Thokala, E L Simpson, P Tappenden, et al.
Pageof 393

Showing results (21-30 of 3,928) with videos related to

Sort By:
Pageof 393
Pharmacoeconomics|January 8, 2016
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling StudyKathryn Coyle, Doug Coyle, Julie Blouin, et al.
Pharmacoeconomics|January 22, 2016
Biosimilars: How Can Payers Get Long-Term Savings?Jorge Mestre-Ferrandiz, Adrian Towse, Mikel Berdud
Pharmacoeconomics|December 31, 2015
Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life CareJoanna Coast, Elisabeth Huynh, Philip Kinghorn, et al.
Pharmacoeconomics|December 31, 2015
Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?Beth Woods, Rita Faria, Susan Griffin
Pharmacoeconomics|February 11, 2016
Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search RequirementSuzy Paisley
Pharmacoeconomics|May 27, 2016
Model Validation: Has it's Time Come?Jonathan Karnon
Pharmacoeconomics|June 3, 2016
Sustainable Financing of Innovative Therapies: A Review of ApproachesAidan Hollis
Pharmacoeconomics|February 26, 2016
Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and ChallengesSevan Dirmesropian, James G Wood, C Raina MacIntyre, et al.
Pharmacoeconomics|April 13, 2016
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with SchizophreniaKrithika Rajagopalan, David Trueman, Lydia Crowe, et al.
Pharmacoeconomics|February 20, 2016
Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group PerspectiveP Thokala, E L Simpson, P Tappenden, et al.
Pageof 393